Analysis of Bacterial Coinfections in Patients with Mild, Moderate, and Severe COVID-19

This study aimed to analyze the clinical features and infection status of COVID-19 patients with bacterial infections in Shaanxi Province. A retrospective analysis was conducted on 2,000 hospitalized patients from December 2022 to February 2023, categorized into mild, moderate, and severe COVID-19 groups. Among these, 300 patients had bacterial coinfections, with <i>Klebsiella pneumoniae</i> and <i>Acinetobacter baumannii</i> identified as the main pathogens. The study found a higher male prevalence and a higher median age, with severe cases mostly affecting individuals aged 70-90 years. The drug resistance rates of patients with mild and severe COVID-19 were low. Patients with severe COVID-19 were mainly infected with carbapenem-resistant Enterobacterales (CRE), carbapenem-resistant <i>A. baumannii</i> (CR-Ab) and extended-spectrum β-lactamase producing bacteria (ESBLs (+)). The findings highlight the importance of rational antibiotic use for severe COVID-19 patients to prevent the development of multidrug resistance caused by empirical medication and to provide a basis for clinical medication.